Genmab A/S (CSE: GEN and Neuer Markt: GE9D), Copenhagen, Denmark, has entered a new collaborative agreement with Immunex Corporation (Nasdaq: IMNX) to discover and develop a fully human antibody against a proprietary Immunex cancer target.
FORMA Therapeutics announced today that it entered into an agreement granting Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), exclusive worldwide rights to acquire a pre-clinical small molecule program against a single undisclosed cancer target.
As per the terms of the partnership, Ablynx will provide access to novel nanobodies against a specific, undisclosed cancer target, and Spirogen will provide access to its proprietary cytotoxic warheads (PBDs) and conjugation technologies.
Under the agreement, sanofi-aventis will have access to Belfer's cancer target identification and validation platform and translational medicine capabilities, and an exclusive licence option to develop, manufacture and commercialise the compounds directed at the targets identified and validated under the research collaboration.
Key Topics Covered: 1 Executive Summary 2 About Cancer Highlights 3 Methodologies 4 Table of Contents 5 How to Use this Report 6 Breast Cancer Target Localization 7 The Cancer Genome Project and Breast Cancer Targets 8 Protein Expression Profiles of Breast Cancer Drug Targets in Human 9 Pathway Analysis of Breast Cancer Drugs 10 Protein-Protein Interactions Among Identified Breast Cancer Targets 11 Available Biological Structure Data on Breast Cancer Targets 12 Drug Target Profiles of Breast Cancer Drugs 13 The Drug-Target Interactome 14 The Progression and Maturity of Breast Cancer Targets 15 Targets by Major Therapy Strategies in Breast Cancer 16 Breast Cancer Targets by Companies 17 Disclaimer 18 Drug Index 19 Company Index